Award Number: DAMD17-98-1-8303

TITLE: Alteration in the Nuclear Structure of Breast Cancer Cells in Response to ECM Signaling

PRINCIPAL INVESTIGATOR: Wen-Man Liu, Ph.D.

CONTRACTING ORGANIZATION: University of California at Berkeley for Performance at Ernest O. Lawrence Berkeley National Laboratory Berkeley, California 94720

REPORT DATE: September 1999

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Alteration in the Nuclear Structure of Breast Cancer Cells in Response to ECM Signaling

Wen-Man Liu, Ph.D.

University of California at Berkeley for Performance at Ernest O. Lawrence Berkeley National Laboratory Berkeley, California 94720
E-MAIL: WMLiu@lbl.gov

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

Eukaryotic chromosomes are thought to be separated into topologically independent loop domains by periodic attachment onto an intranuclear frame known as the nuclear matrix. Specific DNA sequences that bind to the nuclear matrix are called matrix attachment regions (MARs), in which a specialized DNA context sequences exhibiting high base unpairing propensity (BUR) is typically found. Besides organization of eukaryotic DNA, BUR/MARs may also be important for various functions including replication, transcription and recombination. A strong BUR-binding protein, p114, previously isolated from breast carcinoma cells, was identified as to be poly ADP-ribose polymerase (PARP). Depleting PARP by antisense construct in MDA-MB-231 cells resulted in the loss of aggressive phenotype in vitro, suggesting a critical role for PARP in the onset and/or maintenance of the malignant phenotype. Additionally, HMG I(Y) was also found to be BUR-binding protein, and its expression was well correlated with aggressive breast cancer cells. Using three directly comparable cell systems, we demonstrated that the level of HMG I(Y) expression is dynamically regulated in human breast cancer cells in response to varying types of signaling that affect metastatic ability, including the HRG-erbB pathway and those from extracellular matrix (ECM). Finally, to investigate changes in loop domain structure upon three-dimensional alveolar formation induced by ECM, β-casein gene was chosen here for future study.
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature] [Sept. 1, 1999]

PI - Signature Date
TABLE OF CONTENTS

FRONT COVER
STANDARD FORM (SF) 298
FOREWORD
TABLE OF CONTENTS
INTRODUCTION
BODY OF REPORT
APPENDICES
INTRODUCTION

We identified a protein with 114 kDa (p114) from breast carcinoma cells that exhibit a strong binding activity to a specialized DNA context sequences that exhibit high base unpairing propensity. Such a base unpairing region (BUR) is typically found in nuclear matrix attachment regions (MARs); and are thus a hallmark thereof (reviewed in Kohwi-Shigematsu and Kohwi, 1997). BURs/MARs are thought to be important for functional organization of eukaryotic DNA (Gasser and Laemmli, 1987). The BUR-binding activity of this protein (p114) was detected in human breast tumor specimens, but it was virtually undetectable in normal breast counterparts (Yanagisawa et al., 1996). The activity correlated with progression of breast cancer: stronger activity was detected in more aggressive breast cancer than in more differentiated breast cancer. P114 was identified to be poly ADP-ribose polymerase (PARP) (Galand and Kohwi-Shigematsu, 1999). This finding that PARP can recognize primary sequences such as BURs was totally unprecedented (Galand and Kohwi-Shigematsu, 1999). We hypothesized that the interaction between PARP and MARs in breast cancer cells may be critical for the onset and/or maintenance of the malignant phenotype. My recent study showed that a very aggressive human breast cancer cell line, MDA-MB-231 when stably transfected with an antisense PARP expression construct, lost anchorage independent growth capability and its strong invasive phenotype in vitro (see preliminary results).

Additionally, a doublet of 20 kDa proteins were purified by a BUR affinity column from human breast carcinoma cells. These proteins were identified as the high mobility group protein, HMG I, and its splicing variant, HMG Y, which specifically bind BURs. We systematically analyzed whether a substantial increase in HMG I(Y) expression is indeed correlated with breast cancer cells that have metastasizing ability. We found this to be the case using three directly comparable systems: estrogen-dependent MCF-7 cells with and without heregulin cDNA expression; metastasizing MDA-MB-231 cells with and without antisense heregulin cDNA; and MDA-MB-231 cells before and after treatment with metalloproteinase B (MMP-9) chemical inhibitor. (please see attached manuscript entitled “HMG I(Y) Recognizes Base-Unpairing Regions of Matrix Attachment Sequences and Its Increased Expression is Directly Linked to Metastatic Breast Cancer Phenotype”, Liu et al., in press)

We will study changes in loop domain structure upon three-dimensional alveolar formation induced by an extracellular matrix (ECM). For this purpose, we have selected the β-casein gene which expression requires the formation of an ECM-induced three-dimensional alveolar structure (reviewed in Roskelley et al., 1995). Using the genomic sequence information that corresponds the first exon of the β-casein gene, three BAC clones were obtained for the gene locus from the mouse BAC library (Genome System Inc.). Five potential BURs are identified from these BAC clones and under analysis.

In summary, the expression of BUR-binding proteins is well correlated with the aggressive phenotype of breast carcinoma cells. Specific binding to BURs in cancers may participate in gene regulation to trigger or maintain the malignant phenotype in response to signals from ECM, or during progression of tumorigenesis and differentiation. The research plan will provide an important insight into the fundamental mechanism underlying breast cancer development and/or maintenance, and may provide a clue for breast therapy in the future.
BODY OF REPORT

SPECIFIC AIM 1. To fully establish the correlation between p114 MAR-binding activity and the alteration of cell shape associated with either normal or malignant phenotype. To determine whether p114 MAR-binding activity is critical for the cause/or maintenance of the malignant phenotype.

PROGRESS 1: This p114 protein was identified to be poly ADP-ribose polymerase (PARP) which, besides DNA ends and nicks, can also recognize primary sequence of BUR (Galand and Kohwi-Shigematsu, 1999). My antisense approach showed that depleting PARP by expressing antisense PARP RNA in one of the most aggressive human breast cancer cells, MDA-MB-231, led to the loss of anchorage independent growth in soft agar, and a dramatic reduction in the invasive phenotype of these cells \textit{in vitro} (my data are shown in the Preliminary Results). The immediate future experiment will be testing these antisense PARP cells in nude mice.

PRELIMINARY RESULTS:
1). A high level of PARP expression in breast carcinoma cells in not simply because these cells have a high rate of proliferation. MDA-MB-231/antisense-PARP cells showed similar proliferation as the wild type MDA-MB-231 cells in plastic culture dishes (Fig. 1A, 1B).
2). MDA-MB-231/antisense-PARP clones lost ability to grow in soft agar in an anchorage-independent fashion (Fig. 2A, 2B).
3). MDA-MB-231/antisense-PARP clones exhibit significantly reduced invasive activity \textit{in vitro} by Boyden Chamber Assay (Fig. 3); and changed cell morphology when cells were grown in matrigel culture (Fig. 4).

\textbf{Figure 1.} Western analysis of PARP and determination of doubling time for MDA-MB-231/V, AS1, AS2, and AS3 cells, (A) Twenty µg proteins extracted from V, AS1, AS2, and AS3 cells were used in the Western blot analysis using anti-PARP antibody. (B) Cell growths for V, AS1, AS2, and AS3 cells in culture were monitored over 5 days.

\textbf{Figure 2.} Decrease of anchorage independence growth by PARP antisense expression in MDA-MB-231 cells. V, AS1, AS2, and AS3. Soft-agar assays were performed with single wells of six-well dishes by suspending 10,000 cells in 2 ml of 0.3% Noble agar in IMEM/5% FBS containing 400 µg/ml G418 and overlaying the suspension on 2.5 ml of presolidified 0.5% agar in the same medium. The cultures were then overlaid with 2 ml of 0.3% agar in the same medium, covered with another 2 ml medium and changed every 3 or 4 days. At the end of 2 weeks, colonies were stained with the vital stain 2-(4-iodophenyl)-5-phenyltetrazolium chloride (INT) (Sigma) for 72 h at 37°C (Kang and Krauss, 1996). (A) Actual cell dishes for vector control, V, and antisense colonies, AS1, AS2, and AS3. (B) Cells were photographed under a 200X magnification.
Liu, Wen-Man

Figure 4. Reduction of the invasive phenotype of MDA-MB-231 upon PARP depletion by antisense. MDA-MB-231 series cells, V, AS1, AS2, and AS3, were tested in the Boyden chamber assay. Chemoinvasion was measured according to the number of cells transversing matrigel-coated filters. Data points present the mean from quadruplicate from a representative experiment. Standard deviation was calculated for each data point. This assay tends to give variable data due to difficulty in uniformly coating matrigel.

[Boyden Chamber Assay: Methodology for the Boyden chamber assay has been described extensively in previous publications (Thompson et al., 1992). A chemoinvasion analysis was conducted with MDA-MB-231 cells in the Boyden chamber assay. Cells were plated at 10,000 cells/well (in quadruplicate) onto polycarbonate filters (12 μm pore, PVP free, Nucleopore, Pleaston, CA) coated with Matrigel (Collaborative Biochemical Products, Bedford, MA, 1:20 dilution of stock) for the chemoinvasion assays. NIH3T3 fibroblast conditioned media was used as a chemoattractant in the lower chambers and was prepared according to previously established protocols (Thompson et al., 1992). Cells were incubated at 37°C, 5% CO₂/95% air for 6h, filters were then fixed, stained with hematoxylin and cells on the top surface were removed. Filters were mounted onto glass slides and the number of cells which had migrated through the pores were assessed for each treatment group by image analysis systems or by microscopy.]

Figure 5. MDA-MB-231 (PARP antisense) cells have a spheroid-like cell morphology as opposed to stellar-like shape in control cells. [Matrigel Outgrowth Assay: MDA-MB-231 cells were plated at 50,000 cells mixed with 0.2 ml Matrigel (Becton Dickinson Inc.)/well on a present Matrigel layer (0.1 ml) in 12-well plate, covered by IMEM/5%FBS and grown for several days at 37°C, 5% CO₂/95% air.]

Summary: My preliminary results shown here strongly suggest that PARP may be a key player in the maintenance of the aggressive phenotype of breast malignancy.

PROGRESS 2: During this study, I noticed that in the Southwestern blot, there is a small BUR-binding protein (around 20 kDa) was highly expressed in malignant breast cancer cells but not in nonmalignant cells. These doublet of 20 kDa proteins were purified by a BUR affinity column from human breast carcinoma cells and identified as the high mobility group protein, HMG I, and its splicing variant, HMG Y. We show that HMG I(Y) specifically binds BURs. Mutating BURs so as to abrogate their unwinding property greatly reduced their binding affinity to HMG I(Y). Numerous studies have indicated that elevated HMG I(Y) gene expression is correlated with more advanced cancers and with increased metastatic potential. We studied whether the expression of HMG I(Y) responds to signaling through the heregulin (HRG)-erbB pathway and the ECM. HMG I(Y) expression was increased in MCF-7 cells after stable transfection with an HRG expression construct, which led cells to acquire estrogen independence and metastasizing ability. A high level of HMG I(Y) expression was detected in metastatic MDA-MB-231 cells, but the expression was virtually diminished and the metastasizing ability was lost after cells were stably transfected with an antisense HRG cDNA construct. HMG I(Y) was also decreased in MDA-MB-231 cells when treated with a chemical inhibitor for MMP-9 that led to a reduction of invasive
capability in vitro. The level of HMG I(Y) expression, therefore, is dynamically regulated in human breast cancer cells in response to varying types of signaling that affect metastatic ability, including the HRG-erbB pathway and those from ECM (attached manuscript; Liu et al., in press).

CHANGE: P114 was identified as PARP which is known as an enzyme that binds to DNA ends and nicks generated upon DNA damage and contributes to the maintenance of genome stability (reviewed in Jeggo, 1998). It will be difficult to identify the BUR sequences bound to PARP in vivo. Therefore, we have selected the β-casein gene for studying changes in loop domain structure upon three-dimensional formation in response to ECM. The expression of β-casein requires the formation of an ECM-induced three-dimensional alveolar structure (reviewed in Roskelley et al., 1995), which provides an example for up-regulation in response to ECM. For this study, I will use a homogenous murine mammary epithelial cell line, SCp2 (Desprez et al., 1993), which was cloned from a heterogenous culture derived from mid pregnancy mammary glands. SCp2 cells grow well on tissue culture plastic in serum-containing medium. However, when given an exogenous basement membrane and lactogenic hormones in serum-free medium, they cease proliferation form alveolus-like structures, and functionally differentiate, as judged by the expression and secretion of milk proteins. Therefore, with this system, I will be able to examine how higher order chromatin structure changes in response to ECM-induced differentiation that accompanies a distinct morphology of breast epithelial cells.

Using the genomic sequence information that corresponds the first exon of the β-casein gene, three BAC clones were obtained for the gene locus from the mouse BAC library (Genome System Inc.). Using SATB1 and anyi-SATB1 antibody, five potential BURs already were isolated from these BAC clones and under analysis (data not shown). Even though SATB1 is a thymocyte factor, it can bind to the BUR in any cell system in vitro and therefore can be used to clone BUR. Precise methods for this experiment are described in our recent publication (Kohwi-Shigematsu et al., 1997). Once a BUR is identified, I will determine by in situ hybridization whether this site is anchored or not on the nuclear matrix of SCp2 cells when cultured on ECM to form alveolar structure. This will be compared with in situ hybridization with the SCp2 nuclear matrix when the cells were cultured on plastic (without alveolar structure). The result will tell me whether anchoring of this particular BUR is a specific event in response to ECM induced three-dimensional structure. Because I already know the expression status of these genes in response to ECM, I can immediately make a correlation with the loop domain structure and gene expression. As a future experiment, provided that positive results were obtained from the previous experiments, I will explore specific proteins that bind to the BURs isolated. To do this, I will prepare a DNA affinity column using a particular BUR. Protein extracts from ECM-induced SCp2 cells will be used to purify such a protein. This strategy has been published by our laboratory (Kohwi-Shigematsu et al., 1997)

SPECIFIC AIM 2. A set of genomic sequences bound to p114 in vivo in T4-2 cells grown in EHS matrix will be obtained. The association of these sequences with nuclear matrix prepared from T4-2 cells either grown in EHS matrix (tumor phenotype) or where treated with β1-integrin antibody (non-malignant phenotype) will be compared.
[N/A in this period]

SPECIFIC AIM 3. For selected genomic sequences bound to p114 in T4-2 cells grown in EHS culture, specific genes will be identified nearby such genomic sequences. We will determine whether these specific genes expression is regulated by p114 MAR-binding activity altered by ECM signalling.
[N/A in this period]
LITERATURE CITED


Yanagisawa, J., Ando, J., Nakayama, J., Kohwi, Y., and Kohwi-Shigematsu, T. A matrix attachment region (MAR)-binding activity due to a p114 kilodalton protein is found only in human breast
APPENDICES

1. Research accomplishments:
   a. One publication in Cancer Research (in press) “HMG I(Y) Recognizes Base-Unpairing Regions of Matrix Attachment Sequences and Its Increased Expression is Directly Linked to Metastatic Breast Cancer Phenotype”.

   b. Important preliminary results supporting my hypothesis that PARP (p114) may be a key player in the maintenance of the aggressive phenotype of breast malignancy.

   c. Potential BURs isolated from β-casein gene locus.

2. Attached manuscript “HMG I(Y) Recognizes Base-Unpairing Regions of Matrix Attachment Sequences and Its Increased Expression is Directly Linked to Metastatic Breast Cancer Phenotype”
HMG I(Y) Recognizes Base-Unpairing Regions of Matrix Attachment Sequences and Its Increased Expression is Directly Linked to Metastatic Breast Cancer Phenotype.

Wen-Man Liu*, Fabiana K. Guerra-Vladusic*, Shinichi Kurakata#, Ruth Lupu* and Terumi Kohwi-Shigematsu*

*Lawrence Berkeley National Laboratory, University of California, 1 Cyclotron Road, Berkeley, California, 94720.
# Biological Research Laboratories, Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140, Japan.

Running title: A link of MAR-binding proteins to breast cancer metastasis.
Key words: HMG I(Y), matrix attachment region, heregulin, breast cancer and metastasis.
Abstract

Base unpairing regions (BURs) are specialized DNA contexts that confer an exceptionally high unwinding propensity, and are typically identified within various matrix attachment regions (MARs). A BUR affinity column was used to purify a doublet of 20 kDa proteins from human breast carcinoma cells. These proteins were identified as the high mobility group protein, HMG I, and its splicing variant, HMG Y. We show that HMG I(Y) specifically binds BURs. Mutating BURs so as to abrogate their unwinding property greatly reduced their binding affinity to HMG I(Y). Numerous studies have indicated that elevated HMG I(Y) gene expression is correlated with more advanced cancers and with increased metastatic potential. We studied whether the expression of HMG I(Y) responds to signaling through the heregulin (HRG)-erbB pathway and the extracellular matrix (ECM). HMG I(Y) expression was increased in MCF-7 cells after stable transfection with an HRG expression construct, which led cells to acquire estrogen independence and metastasizing ability. A high level of HMG I(Y) expression was detected in metastatic MDA-MB-231 cells, but the expression was virtually diminished and the metastasizing ability was lost after cells were stably transfected with an antisense HRG cDNA construct. HMG I(Y) was also decreased in MDA-MB-231 cells when treated with a chemical inhibitor for MMP-9 that led to a reduction of invasive capability in vitro. The level of HMG I(Y) expression, therefore, is dynamically regulated in human breast cancer cells in response to varying types of signaling that affect metastatic ability, including the HRG-erbB pathway and those from ECM.
Introduction

Specialized genomic DNA sequences that have a high affinity to the isolated nuclear matrix \textit{in vitro} have been designated as matrix/scaffold attachment regions (MARs/SARs) (1-6). MARs were thought to tether chromatin onto the nuclear matrix, thus separating genomic DNA into topologically independent loop domains which may be important for various functions including transcription and replication. For instance, MARs have been shown to be directly linked to biological activity such as cell-type specific regulation (7), demethylation (8) and chromatin accessibility (9).

MARs typically contain a region with a specialized context that possesses an exceptionally high propensity to unwind by contiguous base-unpairing when subjected to negative supercoiling (10, 11). Such a region is referred to as a BUR (base-unpairing region) and typically contains clusters of ATC sequence stretches, a specific sequence context in which one strand exclusively consists of mixed A, T, and C nucleotides (ATC sequences) (reviewed in 12). BURs, when they are in a double-stranded form, are specific targets of cell type-specific factors such as SATB1 predominantly expressed in thymocytes (13) and a B cell factor, Bright (14). Recently, genomic DNA sequences that bind \textit{in vivo} to SATB1 were isolated, and these sequences were shown to be localized at the bases of chromatin loops \textit{in vivo} (15). BURs are also preferential targets of other proteins including nucleolin (16), mutant p53 (17), and p114 which is found in breast carcinoma cells (18). When a BUR is mutated to abrogate the unwinding capability, its affinity to SATB1 is abolished (13) and its affinity to the nuclear matrix is greatly reduced (11).

A group of proteins may exist that bind specifically to BURs in cancer cells and participate in gene regulation to trigger or maintain the malignant phenotype. Here we searched for a BUR-binding protein, the expression of which is well correlated with the aggressive phenotype of breast carcinoma cells that have the metastasizing ability. We detected two proteins that migrate as a doublet on SDS-PAGE at 20 kDa molecular weight, the BUR-binding activity of which is dramatically elevated in highly metastatic breast carcinoma cell lines, but is much less in non-
metastatic breast carcinoma cell lines. The 20 kDa proteins were identified as HMG I(Y), a member of the high-mobility group (HMG) non-histone chromatin proteins. HMG I and HMG Y are splice variants of the same gene located on human chromosome 6p21 (19), which have been demonstrated to strongly bind SARs/MARs (20). Here, we found that HMG I(Y), the combination of HMG I and the splice variant HMG Y, exhibits a strict preference for double-stranded BUR sequences, the key structural element of MARs, over its mutated version that is still AT-rich but has lost the unwinding propensity.

In general, most normal differentiated mammalian cells and adult tissues express extremely low levels of HMG I(Y) mRNA and protein (reviewed in 21). Overexpression of HMG I(Y) was first shown in HeLa cells (22), and since then in various types of tumors in mice and rats (23-28). Interestingly, an antisense construct for HMG I-C, another AT-hook containing HMG protein, has been shown to prevent neoplastic transformation of rat thyroid cells by retroviral oncogenes, and this led to the elimination of the endogenous level of HMG I(Y) proteins (29). Human thyroid neoplasias and thyroid carcinoma cell lines express HMG I(Y) at a high level, while benign follicular adenomas, goiters, and normal thyroid cells do not (30). HMG I(Y) expression has also been observed to increase in various types of human cancer, including prostate cancer (31, 32), colorectal carcinomas (33), uterine leiomyomata (34) and squamous intraepithelial and invasive lesions of the uterine cervix (35). Apparently, HMG I(Y) gene expression associates with the malignant phenotype of human cells and tissues.

Numerous studies have indicated that growth factors and their receptors play an important role in cancer biology. The EGF-like receptor (EGFR) family is a group of transmembrane tyrosine kinases, that is frequently overexpressed in a variety of carcinomas (36-39), and high EGFR levels are associated with poor clinical prognosis (reviewed in 40). Holth et al. (41) have observed an EGF-induced over-expression of HMG I(Y) in the highly metastatic Hs578T, but not in the nonmetastatic MCF7 cells. It suggested that HMG I(Y) may have an important implication concerning the cellular mechanisms involved in the progression of mammary epithelial tumors. Besides EGFR, amplification and overexpression of one of the erbB-receptors, erbB-2, also
correlates with a poor prognosis in some adenocarcinomas, most notably breast cancer (36, 42-48). The activator for erbB-2, heregulin (HRG) originally called gp30 (49), has been suggested to play an important role in breast tumor development (50). HRG is a growth factor originally isolated from hormone independent and invasive breast cancer cells (51, 52). MCF-7 cells can be converted to a more aggressive phenotype and rendered tumorigenic and metastatic in vivo merely by transfecting them with a HRG expression construct (53). On the other hand, transfecting highly metastatic MDA-MB-231 cells with an antisense-HRG construct led to an inhibition of tumorigenic phenotype (54). In order to further address the role of HMG I(Y) in carcinogenesis and to examine the effect of HRG on HMG I(Y) expression, we have undertaken studies in these two cell models of human breast cancer progression. In both cases, the higher level of HMG I(Y) protein was found to be strictly correlated with the high expression of HRG and metastasizing capability of cells.

Proteases that degrade the extracellular matrix ECM, including the serine proteases and matrix metalloproteases (MMP) gelatinase A (MMP-2) and B(MMP-9), have been implicated in various pathological states of growth, invasion and metastasis (55, 56). Inhibition of MMP-9 expression using a ribozyme has been shown to block metastasis in the rat sarcoma model system (57). We report here that blocking MMP-9 activity in MDA-MB-231 cells with an MMP-9 chemical inhibitor resulted in a loss of invasive phenotype in vitro, and a decrease of the HMG I(Y) protein levels. Our observation suggests that the expression of HMG I(Y) can be regulated dynamically in response to various types of signaling that affect metastatic ability, including heregulin and ECM.
Materials and Methods

Cell Lines and Cell Extract Preparation. Breast carcinoma cell lines MDA-MB-453, SK-BR-3, BT-474, MCF-7, Hs578T, BT-549, and MDA-MB-231, were obtained from American Type Culture Collection (Rockville, MD). These cell lines were maintained in IMEM containing 10% fetal bovine serum (Gibco BRL). MCF-7/HRG cells were maintained as described (53). IMEM Phenol Red free media and charcoal-stripped serum were used for experiments looking at the effect of 17β-estradiol in MCF-7 cells. Cells were stimulated for 48 h with Estradiol (E2, 10⁻⁹M) (53), Tamoxifen (Tam, 10⁻⁷M) (53) or anti-estrogen ICI 164,384 (ICI, 10⁻⁷M) (58). MDA-MB-231/AS cell lines were maintained as MDA-MB-231 cells except for the addition of 200 μg/ml G418 (Geneticin, Sigma) into medium. Metalloprotease MMP-9 inhibitor (N-methyl-(3S)-S-[(2R)-2-hydroxyaminocarbonylmethyl-l-oxoundecyl]-hexahydropyridazine-3-carboxamide, a gift from Sankyo Pharmaceutical Company, Tokyo, Japan) was added to MDA-MB-231 cell cultures at the indicated concentrations (2.5, 5 and 10 μM) for six days. In situ cell death detection kit (Boehringer Mannheim) was used for TUNEL assay. Cell extracts were prepared as described (16). Briefly, the cell pellet was resuspended in approximately 5X volume of Dignam's extraction buffer [0.42 M NaCl, 20 mM Hepes (pH 7.9), 25% glycerol, 1.5 mM MgCl₂, 0.2 mM EDTA, 1mM DTT, 0.1 mM Phenylmethylsulfony fluoride, and 10 μg/ml each of leupeptin and aprotinin]. Cells were lysed in a Dounce homogenizer (50 strokes with pestle A) and followed by a brief sonication. The extract was centrifuged for 20 min in a TLA-100 rotor in a Beckman TL-100 ultracentrifuge at 100,000 rpm, and the supernatant was either assayed directly using Southwestern and Western analysis or used for affinity purification of MAR-binding proteins.

Boyden Chamber Assay. Methodology for the Boyden chamber assay has been described extensively in previous publication (58). A chemoinvasion analysis was conducted with MDA-MB –231 cells in the Boyden chamber assay. Cells were plated at 10,000 cells/well (in
quadruplicate) onto polycarbonate filters (12 µM pore, PVP free, Nucleopore, Pleaston, CA) coated with Matrigel (Collaborative Biochemical Products, Bedford, MA, 1:20 dilution of stock) for the chemoinvasion assays. MMP-9 inhibitor (0, 0.1, 0.5, 1, 5, 10, 15, 20 µM) was added to the upper chamber and lower chambers. NIH3T3 fibroblast conditioned media was used as a chemoattractant in the lower chambers and was prepared according to previously established protocols (58). Cells were incubated at 37°C, 5% CO₂/95% air for 6 h, filters were then fixed, stained with hematoxylin and cells on the top surface were removed. Filters were mounted onto glass slides and the number of cells which had migrated through the pores were assessed for each treatment group by image analysis systems or by microscopy.

**DNA Affinity Purification of MAR-binding Proteins and Identification.** The MAR affinity column was prepared exactly as described (Dickinson and Kohwi-Shigematsu, 1995). Briefly, the wild-type complementary oligonucleotides, 5'TCTTTAATTCTAATATA-TTTAGAAAttc3' and 5'TTCTAAATATATTAGAAATTAAAGAgaa3', were annealed, phosphorylated at 5' ends, and ligated to form concatemers (lowercase type indicates single-strand overhangs). Routinely, 200 µg of the double-stranded oligomers was coupled to 1 ml of cyanogen bromide-activated Sepharose 6 MB (Pharmacia). The oligonucleotide 5'TCTTTAATTCTCAGTTTAGAAAttc3' and its complementary strand 5'TTCT-AAGCAGTAGAAATTAAAGAgaa3' were used for generating a mutated MAR DNA affinity column. Cell extract was prepared from approximately 10⁹ cells, incubated with salmon sperm DNA competitors, centrifuged, and diluted with buffer Z [25 mM HEPES (pH7.9), 1.25 mM MgCl₂, 1mM DTT, 20% glycerol, and 0.1% (v/v) NP40] as described previously (18). Cell extract was re-adjusted to 0.1M KCl in buffer Z, loaded on a mutated MAR DNA affinity column, and washed with the same buffer. The bound proteins were eluted with buffer Z containing 0.2, 0.3, 0.4, 0.6 and 1.0 M KCl, and this MAR-binding protein was eluted at 0.3 M KCl. The eluted fraction was re-adjusted to 0.1 M KCl in buffer Z, loaded on a wild-type MAR DNA affinity column, and washed with buffer Z containing 0.1 and 0.2 M KCl. The bound proteins were eluted.
at 0.3, 0.4, 0.5, 0.6, 0.8 and 1.0 M KCl, and this MAR-binding protein was eluted at 0.4-0.6 M KCl. The purified p20 was sent to the Protein Structure Laboratory at University of California at Davis for partial amino acid sequencing analysis.

**RT-PCR and DNA Constructs.** Total cellular RNA was extracted from MDA-MB-231 cells by a one-step acid guanidinium isothiocyanate-phenol procedure using Tri Reagent (Sigma), precipitated with ethanol, and quantitated by spectrophotometry. Five µg total RNA was used for RT-PCR as instructed by the manufacturer (GIBCO BRL). Two hundred units of Super Script II, RNase H Reverse Transcriptase, was added in a typical 20 µl reaction (50 ng specific primer, 5 µg total RNA, 1X First Strand Buffer, 10 mM DTT and 0.5 mM dNTP), and incubated 1 h at 42°C. The reaction was inactivated by heating at 70°C for 15 min. To remove RNA complementary to the cDNA, RNase H was added and incubated at 37°C for 30 min. The purified cDNA was used as a template for amplification in PCR. The primers including BamHI linker for amplification of HMG I(Y) cDNA are 5’-gaaggatccATGAGTGAGT-3’ and 5’-cagggatccAAGGAAGCTTCTCCAGTGA-3’. PCR was then performed in a 50 µl volume including 2.5 units of Taq polymerase, 10x buffer (Promega), 1.5 mM MgCl₂, 200 µM dNTPs, and 2 µM of each primer under the following conditions: 94°C for 5 min; followed by 30 cycles of 94°C for 45 sec, 55°C for 45 sec, and 72°C for 45 sec; followed by 5 min at 72°C. The 372 bp BamHI fragment of HMG I cDNA and the 339 bp BamHI fragment of HMG Y cDNA were cloned into the pGEX-4T-1 vector (Stratagene) to express GST-HMG I(Y) proteins. GST-fusion proteins were synthesized in *Escherichia coli* and purified as described (59). Protein concentrations were determined by using a protein assay kit (Bio-Rad) and by comparing to BSA standards on SDS-PAGE gel stained with commassie blue.

**Southwestern and Western Analysis.** Southwestern and Western blots were done basically as described previously (16) with some modifications. For Southwestern analysis,
protein samples were adjusted to 1X SDS-PAGE loading buffer and incubated at 37°C for 10 min before being applied to a 15% polyacrylamide mini gel layered with 3.75% stacking gel. After electrophoresis, separated proteins were transferred electrophoretically at 45 V/cm at 0.75 mA for 1 h onto Immobilon P membrane (Millipore). The membrane was blocked with 5% BSA in the binding buffer [20 mM Tris-HCl (pH 7.6), 50 mM NaCl, 1 mM DTT, and 0.25% BSA] at RT for 1-2 h. To 20 ml of binding solution, heat-denatured salmon sperm DNA to a final concentration of 50 μg/ml was added, and the membrane was preincubated at RT for 30 min. 32P-labeled probe (approximately 10^8 cpm/μg DNA) was added and further incubated for 40 min at RT. The membrane was washed four times for 10 min in binding buffer. It was then exposed to XAR film.

For Western blot analysis, proteins separated by SDS-PAGE were electrophoretically transferred to Immobilon P membranes (Millipore) in 20 mM sodium phosphate buffer (pH 6.8). Prestained broad range protein marker (Bio-Rad) was included for internal molecular mass standards. The filter was blocked in 5% BSA in TST [20 mM Tris-HCl (pH 7.6), 0.5 M NaCl, and 0.05% Tween20], washed in TST buffer minus BSA, and incubated at RT for 1.5 h with either polyclonal antibody to HMG I(Y) (from Santa Cruz Biochemicals or a generous gift obtained from Dr. Vincenzo Giancotti) at a 1: 200 dilution, or monoclonal anti-β-actin antibody (Sigma). After being washed in TST, the filter was incubated with a 1:10,000 dilution of rabbit anti-goat, goat anti-rabbit or mouse IgG horseradish peroxidase conjugate. Following extensive washing in TST, the blots were incubated with ECL (enhanced chemiluminescence) reagent solutions (PIERCE) and exposed to XAR film for visualization of protein bands. Quantitation of Southwestern and Western blots were done individually by phosphorimager and densitometer (Storm 860, Molecular Dynamics).

**Gel-mobility Shift Assay.** The experiment was performed basically as described (16). Binding reactions were done in 20 μl total volume containing 10 mM Hapes (pH 7.9), 1 mM DTT, 50 mM KCl, 2.5 mM MgCl2, 10 % glycerol, 1 μg double-stranded poly (dI-dC), 10 μg BSA and
2.5 ng – 120 ng GST-HMG I or Y protein. Samples were preincubated at room temperature (RT) for 5 min before radiolabeled DNA probe was added. The Bam HI-Hind III fragments of wild-type (25)$_7$ and mutated (24)$_8$ (13), or the EcoRI fragments of wild-type and mutated IgH 3'MAR (5), were end labeled by the klenow fragment of DNA polymerase and used as DNA probes in the present study.
Results

Increased MAR-binding Activity of Small Proteins (20 kDa) in Metastatic Breast Cancer Cells. To investigate BUR-binding proteins that might be correlated with the aggressive phenotype of breast carcinomas, we chose to examine seven human breast carcinoma cell lines (listed in Table 1). High levels of HRG expression have been observed in aggressive breast cancer cells (Hs578T, BT-549 and MDA-MB-231) that are vimentin positive/estrogen receptor (ER)-negative, invasive on matrigel outgrowth assay, and metastatic in vivo in nude mice (50, 60, 61). In contrast, MDA-MB-453, SK-BR-3, BT-474 and MCF-7 are representatives of non-metastatic breast cancer cell lines with no detectable level of heregulin (HRG) (50, 60, 61) or vimentin proteins (58). Using whole cell extracts from these cells, we performed Southwestern analysis using the synthetic MAR probe, wild type (25). This multimer contains the 25 bp sequence that was derived from a MAR 3' of the IgH enhancer and contains the core unwinding element (10). Wild type (25), has a base-unpairing property, thus it is a BUR, and binds to the nuclear matrix with high affinity (11). Interestingly, the BUR-binding activity of small proteins (Fig. 1, 20 kDa, arrowhead) is remarkably higher in aggressive metastatic cells (Fig. 1, lane 5 - lane 7) as compared to non-metastatic cells (Fig. 1, lane 1 - lane 4). Three bands were seen at small protein range, a doublet p20(s) and a very faint band around 15 kDa. Larger proteins on the same Southwestern blot exhibited an overall similar and relatively weaker BUR-binding activity (Fig. 1). This result suggests a possible correlation between increased BUR-binding activity of small proteins and the progression of breast cancer cells to a metastatic phenotype. The same Southwestern blot was directly subjected to Western blot analysis using anti-β-actin antibody (Fig. 1, bottom panel). Each sample was precisely quantitated for its protein amount before loading. There was some variation in the β-actin expression depending on different cell lines. However, the strong MAR-binding activity detected in metastatic cells, especially MDA-MB-231, is
apparently not due to an excess protein load (compare Fig. 1, lanes 1, 2 to lanes 5, 7, for example).

Southwestern blot analysis using a mutated \((24) \_8\) probe was performed for MDA-MB-231 cells. This mutated DNA was derived from the original 25 bp sequence by specifically mutating the core unwinding element to abrogate the unpairing propensity (10). The 20 kDa proteins bound poorly to the mutated \((24) \_8\) on the Southwestern blot (data not shown), suggesting that these proteins are BUR-binding proteins similar to SATB1 (13) and nucleolin (16).

**Purification and Identification of a 20 kDa MAR-binding Protein from MDA-MB-231 Cells.** To purify 20 kDa MAR-binding proteins, wild-type and mutated MAR DNA affinity columns were prepared by coupling multimers of either the wild-type 25 mer oligonucleotide or the mutated 24 mer oligonucleotide to activated Sepharose as described in Materials and Methods. The strategy for purifying this p20(s) from MDA-MB-231 cell extracts is first to allow p20(s) to bind the multimerized mutated \((24)n\) DNA affinity column by passing through the column three times under low salt conditions. Then, the eluted fractions were applied onto the multimerized wild-type \((25)n\) DNA affinity column. Following this protocol, a major band of 20 kDa was purified by BUR-affinity chromatography and stained with comassie blue (Fig. 2A). The purified protein and proteins in the crude extract were analyzed side-by-side by Southwestern blot analysis, confirming that the 20 kDa BUR-binding protein was purified (Fig. 2B). Previously identified p114 (18) were purified from the same column at higher salt concentrations beyond 0.6M. Sequencing of two peptide fragments obtained by tryptic digestion of the gel-purified 20 kDa protein, KQPPVSPGTALVGOSK and EPSEVPTPK, revealed their identity with the published sequence of human HMG I (62). HMG I (11 kDa) migrates as a 20 kDa protein in a 15% SDS-PAGE gel. Western blot analysis using anti-HMG I(Y) antibody indicated that increased MAR-binding activity detected in human metastatic breast cancer cells (Fig 1, lane 5 - lane 7) was due to the elevated HMG I protein (see Fig. 2C). An additional protein that migrates slightly faster than HMG I is also recognized by anti-HMG I(Y) after longer exposure (see Fig. 2C, bottom panel). This is most likely an isoform of HMG I, the HMG Y, which is produced by
alternative splicing of mRNA transcripts from a single gene. This may explain the appearance of a doublet on the Southwestern blot around Mr. 20,000 (Fig.1). We therefore conclude that the two MAR-binding proteins that migrate close to 20kDa from MDA-MB-231 cells are HMG I(Y).

**GST-HMG I(Y) Fusion Proteins Selectively Bind BURs.** To prepare glutathione-S-transferase (GST)-fused HMG I and HMG Y proteins, HMG I(Y) cDNAs were cloned by RT-PCR strategy using RNA from MDA-MB-231 cells. The 372 bp fragment of HMG I cDNA and the 339 bp fragment of HMG Y cDNA were separately cloned into the pGEX-4T-1 vector (Stratagene). GST-HMG I(Y) fusion proteins purified from bacteria were examined by gel mobility shift assay using wild-type (25)$_7$ and mutated (24)$_8$ (Fig.3A). Both GST-HMG I and HMG Y bound with strong affinity to wild-type (25)$_7$, with an estimated dissociation constant (kd) in the range of 4 x 10$^{-9}$ M (Fig. 3A, upper panel) under conditions of protein excess (Dickinson and Kohwi-Shigematsu, 1995). In contrast, these proteins exhibited dramatically reduced binding affinity, by at least 2 orders of magnitude, to the mutated (24)$_8$ (Fig. 3A, bottom panel). This indicates that HMG I(Y) has a remarkable specificity toward the wild-type (25)$_7$ probe as opposed to the mutated (24)$_8$ probe, even though these probes are both A+T-rich (see Material and Methods).

To further examine whether it is a general phenomena that HMG I(Y) selectively binds BUR, a gel-mobility shift assay was performed using the native MAR of 300 bp located 3’ of the enhancer and the mutated version in which the core unwinding element, ATATAT, is specifically mutated to CTGTCT (Fig. 3B). The 300 bp MAR 3’ of the IgH enhancer is 70% A+T rich and the three nucleotide mutations do not significantly alter the overall AT content, and yet the mutation completely abrogates the unwinding property of this MAR (10). As shown in Figure 3B, GST-HMG Y specifically bound wild-type IgH 3’MAR, but not the mutated IgH 3’ MAR. Similar results were also found for GST-HMG I (data not shown). Russnak et al. (63) has shown that, under the appropriate conditions, HMG-I exhibits different affinities to some A+T rich sequences. Consistent with the previous report that HMG I(Y) strongly interacts with SARs/MARs (20), our
data clearly demonstrated again that HMG I(Y) is not just a nonspecific A+T-rich DNA binding protein but has a binding specificity for BUR.

**HMG I(Y) Expression Is Increased in MCF-7 Cells upon Estrogen Treatment or Heregulin cDNA Transfection.** Estrogen is known to increase cellular proliferation and activation of estrogen responsive genes in MCF-7 cells, an estrogen receptor (ER) positive cell line (64). Because HMG I(Y) is expressed at elevated levels in proliferating and undifferentiated cells (62), it was of interest to determine if estrogen had any effect on HMG I(Y) expression. Holth *et al.* (41) have shown that estrogen has no significant effect on upregulating HMG I(Y) expression determined by Northern blot analysis. However, by Southwestern and Western analysis, we observed a small induction of MAR-binding activity of HMG I(Y) in MCF-7 cells when they were exposed to estradiol (Figs. 4A and 4C). Two anti-estrogen drugs, Tamoxifen (Tam) and anti-estrogen ICI 164,384 (ICI), completely abolished this induction, indicating that estrogen stimulation of MAR-binding activity was mediated through the ER pathway (Fig. 4A).

HRG is a growth factor expressed in about 30% of invasive breast cancers, and it activates the *erbB* receptor pathway (reviewed in 61). As shown in Table 1, HRG expression correlates with the invasive and metastatic phenotypes of breast cancer cells *in vitro* and *in vivo* (50). HRG is inversely correlated with ER expression. To study the role of HRG in breast cancer tumor progression, Tang *et al.* (53) developed a breast cancer progression model by transfecting an HRG expression construct to an ER positive cell line, MCF-7. MCF-7/HRG-transfected cell clones, which expressed a relatively high level of HRG, developed estrogen independence and resistance to anti-estrogen drugs *in vitro* and *in vivo* (53, 65). This is consistent with a more aggressive hormone-independent phenotype. Wild-type MCF-7 cells are known to be non-tumorigenic in the absence of estrogen and these cells never metastasize in nude mice, even in the presence of estrogen. However, all MCF-7/HRG clones having similar proliferation rates, for example T2, T6, and T7, can form large tumors in nude mice in the absence of an estrogen supplement (65). Tumors generated from T2 and T7 cells (but not T6) became metastatic and developed lymphatic invasion (65). The MCF-7/HRG cell series, therefore, provides a system to study the aggressive
tumor progression in breast cancer. Southwestern and Western analysis of HMG I(Y) were performed for T2, T6, T7, and control MCF-7 cells transfected with vector only. As expected, two metastatic clones, T2 and T7, had significantly increased BUR-binding activity (Fig. 4B) attributed to the elevated level of HMG I(Y) protein (Fig. 4C). In contrast, MCF-7 cells treated with estrogen and T6 cells expressed the same low level of HMG I(Y) as the control MCF-7 cells (Fig. 4C).

Previously, HMG I(Y) expression was shown to be induced by EGF (epidermal growth factor) in metastatic Hs578T cells but not in non-metastatic MCF-7 cells (41). Without induction, no difference of HMG I(Y) mRNA was detected between Hs578T and MCF-7 cells by primer extension and Northern blot analysis (41). However, our Southwestern (Fig. 1) and Western analyses (Fig. 2C) clearly showed that the protein level and BUR-binding activity of HMG I(Y) are both remarkably higher in metastatic cell lines (including Hs578T) than in non-metastatic cell lines (including MCF-7) (see Fig. 2C). Based on our data, there is an association between HMG I(Y) protein level, expression of HRG and malignant phenotype of human breast cancer cells.

It is noteworthy that the protein level and BUR-binding activity of HMG I(Y) in T2 or T7 cells that can metastasize are still much lower than the activity in MDA-MB-231 cells (Fig. 4B). Levels of HMG I(Y) vary dramatically between cell types; for instance, three metastatic cell lines, Hs578T, BT-549, and MDA-MB-231, express different levels of HMG I(Y) even under similar culture conditions (Fig. 1 and Fig. 2C). Therefore, an absolute amount of HMG I(Y) protein or its DNA-binding activity, per se, is apparently not the determinant factor for metastasis. However, in a given cell line, the level of HMG I(Y) consistently increases as it becomes more aggressive (due to overexpression of HRG, for example), and decreases as it becomes less aggressive (reduction of HRG expression, see below).

**HMG I(Y) Expression Is Reduced in MDA-MB-231 Cells Transfected with a Heregulin Antisense Construct.** Since MDA-MB-231 cells are highly metastatic and express high levels of heregulin (50, 53), we studied the effect of reducing the heregulin levels on HMG I(Y) expression by stably transfecting these cells with antisense HRG construct. A series of
stably transfected MDA-MB-231 cell clones were prepared. Cells harboring pRV/CMV vector only (a control called AS-V), and three other cell clones (AS-C6, AS-C23, and AS-C31) transfected with an anti-sense HRG construct showing much reduced levels of HRG expression, were isolated for further analysis. These MDA-MB-231 cells transfected with heregulin antisense HRG-construct have lost metastasizing ability in nude mice (54). Western blot analysis using anti-HMG I(Y) antibody has shown that HMG I(Y) protein levels in all three antisense-HRG cells, AS-C6, AS-C23, and AS-C31, were either dramatically decreased or undetectable (Fig. 5A). This result suggests that the HMG I(Y) level decreased concomitantly with the loss of metastatic phenotype due to the disruption of HRG expression. This result is consistent with our previous results obtained from the studies with MCF-7/HRG cells (Fig. 4C) that the metastatic potential of breast cancer cells is associated with elevated HRG and HMG I(Y) levels.

**Treatment of MDA-MB-231 Cells with a Chemical Inhibitor for MMP-9 Reduced the Levels of HMG I(Y).** It is generally believed that one key element of the metastatic process is the enhanced proteolysis of both basement membrane and stromal extracellular matrix (ECM). Among the proteinase capable of degrading these barriers are the matrix metalloproteinases (MMPs). The gelatinase A (MMP-2) and B (MMP-9) are two members of the MMP family which have been implicated in breast cancer tumor progression (55, 56). MDA-MB-231 cells appear to secrete a significantly high level of MMP-9 activity as compared with MCF-7 cells (R. Lupu, unpublished result). Inhibition of MMP-9 expression using a ribozyme has been shown to block metastasis in the rat sarcoma model system (57). Consistently, confluent MDA-MB-231 cells treated with a chemical inhibitor for MMP-9, N-methyl-(3S)-2-[(2R)-2-hydroxyaminocarbonylmethyl-1-oxoundecyl]hexahydropyridazine-3-carboxamide in the range of 0.1 to 20 μM concentration, resulted in a significant reduction in the invasive phenotype in vitro determined by the Boyden chamber assay (Fig. 5B). At a 10 μM concentration of the inhibitor, the effect became saturated and exhibited approximately 70% inhibition of the invasive activity. The morphology of MDA-MB-231 cells changed from stellar-like to steroid-like shape after treatment.
with the MMP-9 inhibitor as revealed by the matrigel outgrowth assay (R. Lupu, unpublished result). The chemical inhibitor used in this study has an IC50 value of 38 nM for gelatinase A and an IC50 value of 1.2 nM for gelatinase B, and therefore has a high specificity for the latter (66). To examine the effect of the MMP-9 inhibitor on HMG I(Y) expression in MDA-MB-231 cells, these cells in culture at different densities were treated with this MMP-9 specific inhibitor (see Materials and Methods), and their HMG I(Y) expression was measured by Southwestern and Western blot analyses. When subconfluent cells were treated with the MMP-9 inhibitor for 6 days at varying concentrations (1, 2.5, 5 and 10 μM), no significant changes in the level of HMG I(Y) were detected (data not shown). However, when confluent cells were treated with the MMP-9 inhibitor, we observed the gradual decay of HMG I(Y) with the increasing concentration of the MMP-9 inhibitor (Fig. 5C). The MMP-9 inhibitor treatment (10 μM for six days) reduced HMG I(Y) protein levels down to 30% of the original level based on Western analysis (Fig. 5C). Although Southwestern analysis is not as quantitative as Western blot analysis, both assays independently showed an inverse correlation between the concentration of the MMP-9 inhibitor and expression of HMG I(Y). In parallel, the apoptotic cell death had been quantitated by TUNEL assay, because some of the effect maybe due to induction of apoptosis in cells treated with the MMP-9 inhibitor. However, there is no difference on cell viability observed (data not shown) under the conditions used. These data suggest that an alternation in the extracellular matrix by inhibiting MMP-9 resulted in the down regulation of HMG I(Y) expression. Our results show that, similar to the effects of growth factor such as heregulin, HMG I(Y) expression is sensitive to signaling from ECM.
Discussion

Identification of BUR-binding and Metastasis Associated Proteins as HMG I(Y). We detected proteins of ~20 kDa in aggressive human breast carcinoma cells that bind strongly to BURs with a specialized ATC sequence context with high base-unpairing propensity. Using DNA affinity chromatography, a 20kDa protein was purified and identified as HMG I. Another protein with a slightly smaller mass that also confers similar binding specificity was found to be the splicing variant, HMG Y. We demonstrate that HMG I(Y) specifically recognizes BURs: when mutated at specific sites within BURs to abrogate this propensity, HMG I(Y) binding to BURs was either abolished or greatly reduced. This binding specificity of HMG I(Y) for double-stranded BURs is remarkably similar to that of the previously cloned MAR-binding protein SATB1 (13). SATB1 binds along the minor groove with very little contact with the bases, suggesting that SATB1 recognizes the ATC sequence indirectly through the altered sugar-phosphate backbone structure presumably formed due to unusual DNA context.

There are several reports describing the binding specificity of HMG I(Y) proteins (63, 67-69). These studies have shown that HMG I(Y) proteins preferentially bind to the minor groove of A+T-rich B-form DNA (67,68), and yet these proteins do not bind to all stretches of A+T-rich DNA with equal affinity (63). Some study suggests that structure of DNA, rather than the primary sequence per se, is a dominant factor that controls HMG I(Y) binding specificity (69). The present study that demonstrated that HMG I(Y) specifically bind to BURs, the key structural elements of MARs, may have an important implication in cancer. BURs are the in vivo targets of a cell type-specific MAR-binding protein (15), and ablation of the MAR-binding protein caused major deregulation of multiple genes (70). Furthermore, our most recent study has shown that at least one such BUR is an origin of replication in the human tissue culture system. Not limited to the case of HMG I(Y), but an increase in another BUR-binding protein for more aggressive breast cancer was previously reported (18). BURs could be important genomic loci at which many
regulatory events may take place. Any alternation at these loci, including the level of binding proteins, could lead to malignancy or is necessary to maintain the malignant phenotype.

**Association Between HMG I(Y) Expression and Malignant Phenotype in Human Breast Tumor Cells.** We examined the changes in HMG I(Y) levels using directly comparable systems using the same cell lines that either express or do not express heregulin. Specifically, we compared non-metastatic MCF-7 cells with MCF-7 cells containing an HRG cDNA construct that became metastatic, and metastatic MDA-MB-231 cells with MDA-MB-231 cells containing an antisense HRG construct that became non-metastatic. This series of experiments allowed us to systematically examine how HMG I(Y) expression varies with malignant progression in human breast cancer cells. Our results were consistent: heregulin overexpression that promoted metastasizing ability resulted in an increase of HMG I(Y) expression, and conversely the reduction of heregulin that blocked metastasis led to a reduction in HMG I(Y) expression. MDA-MB-231/antisense HRG cells have a similar growth rate on plastic culture as compared to vector control cells (54), suggesting that the net expression of HMG I(Y) is not merely a factor of proliferating activity of cells. This demonstrates that there is a direct correlation between an increased HMG I(Y) protein level and high heregulin expression that is linked to metastatic potential in human breast cancer cells, independent of their relative rates of cell proliferation, at least under the experimental condition employed.

We also examined the effect of an MMP-9 chemical inhibitor on the expression of HMG I(Y) in MDA-MB-231 cells. The gelatinase B (MMP-9) is a member of the matrix metalloproteinases (MMPs) which are zinc dependent endopeptidases implicated in cancer invasion and metastasis (56). MMP-9 is known to cleave native collagens of type IV, V and XI, and elastin (reviewed in 71). Blocking MMP-9 activity in MDA-MB-231 cells with the MMP-9 chemical inhibitor resulted in a loss of invasive phenotype *in vitro*, and a decrease of the HMG I(Y) protein levels. The results indicate that disrupting MMP-9 in the extracellular matrix reduced the expression of HMG I(Y). Blocking function of ECM proteinases can decrease tumor growth (57,
72, 73). Therefore, it is conceivable that a specific signalling pathway(s) is affected due to the MMP-9 inhibitor such that cancer cells become less aggressive as evidenced by the result of Boyden Chamber assay (Fig. 5B). HMG I(Y) expression may be a downstream event and decrease in its expression might be one of the nuclear responses to ECM modification.

Based on our results, it appears that the absolute amount of HMG I(Y) is not a determining factor for the metastatic phenotype. For example, MMP-9 inhibitor treated cells still retained a high level of HMG I(Y), although it was reduced in comparison to the original levels. Therefore, changes in the level of HMGI(Y) expression appear to correlate with or reflect the changes in the status of malignancy of given breast carcinoma cells.

**Potential Role of HMG I(Y) in Breast Cancer.** Transcriptional control has become a major focus in current cancer research. Transcription of the HMG I(Y) gene is predicted to be tightly regulated, and has been shown specifically to be induced in human cells by phorbol esters (74), calcium ionophores (75) and EGF (41), and upregulated by human papillomavirus type 16 E6 protein (76) and tumor promoter (28) in mouse cells. The transcriptional regulation and functional role of HMG I(Y) in cancer development are, however, essentially unknown.

Several functions for HMG I(Y) proteins have been proposed, including nucleosome phasing (77), involvement in the 3' end processing of mRNA transcripts (63, 78), and the amplification of autonomously replicating sequences (79). HMG I(Y) proteins have been demonstrated to be involved in both positive and negative regulation of genes containing A+T-rich regions of DNA, possibly by functioning as accessory "architectural transcription factors" (80-86). HMG I(Y) proteins also appear to bind specifically to regions of putative mammalian cell origins of replication (87) and to G/Q and C-bands of metaphase chromosomes (88). More recently, three distinct sub-nuclear populations of HMG I(Y) have been demonstrated (89), suggesting they may be required for chromosome structural change during cell cycle. An increase in HMG I(Y) gene expression associated with progression in the malignant phenotype may have effects on any combination of these molecular interactions.
The nuclear matrix is believed to play critical roles in regulating many key biological reactions in the nucleus such as gene transcription, DNA replication, DNA organization, and RNA splicing and processing (reviewed in 90). Our data suggest that HMG I(Y) interacts with BURs, the key structural element of MARs. HMG I(Y) may assemble specific three dimensional transcription and/or replication complexes at BUR sites. If so, this may cause detachment of the sites from the nuclear matrix, by successfully competing BURs sites from other MAR-binding proteins, and subsequently alter the loop domain structure of chromatin. It would be interesting to explore this possibility in the future.

Acknowledgments

This work was supported by the National Institutes of Health (RO3 CA70824 to T. Kohwi-Shigematsu) and the U.S. Department of Energy under contract No. DE-AC03-76SF00098; and by the U.S. Army BCRP DAMD 17-98-1-8303 to W.-M. Liu, the RO1-DK to R. Lupu and the UCBCRP to F. Guerra-Vladusic. This work was also supported by Sankyo Co., Ltd. which provided equipment funds. The authors thank our colleagues, Drs. Sanjeev Galande and Miaw-Sheue Tsai, for technical assistance and valuable discussion.
Figure Legend

Figure 1: The high level of MAR-binding activity due to small molecular-weight proteins (around 20 kDa) occurs in human metastatic breast carcinoma cells (lane 5 - lane 7) but not in non-metastatic cells (lane 1 - lane 4). Southwestern blot analysis was performed to investigate MAR-binding activity. Twenty five μg of proteins in cell extracts were loaded on a 15% SDS-polyacrylamide gel. After electrophoresis, the proteins were renatured, then the gel was blotted and hybridized with the radiolabeled wild-type (25), probe. The same amount of proteins used in the Southwestern blot was subjected to Western blot analysis using anti-β-actin antibody.

Table 1: Non-metastatic vs. metastatic human breast cancer cell lines

(NT: Non Tumorigenic)

Figure 2: The 20 kDa protein was identified as HMG I(Y). (A) Affinity purification of a MAR-binding protein from a breast carcinoma cell line, MDA-MB-231. Commassie blue staining analysis was performed for 40 μg protein of a crude cell extract prepared from the MDA-MB-231 cells (Crude) and column-purified p20 from the MDA-MB-231 cell extract (Purified). M, molecular size marker. Arrowhead, p20. (B) Southwestern blot analysis using radiolabeled wild-type (25), as the probe was performed with the same crude extract and purified fraction (1/100) from (A). (C) Western blot analysis using anti-HMG I(Y) antibody was performed for 25 μg protein of cell extracts prepared from human breast carcinoma cell lines. M, molecular size marker. Top panel, shorter exposure. Bottom panel, longer exposure.

Figure 3: Gel-mobility shift assay was performed for GST-HMG I and GST-HMG Y with a radiolabeled wild-type (25), probe (A, top panel), a mutated (24), probe (A, bottom panel), a wild-
type or a mutated IgH 3’MAR probe (B, left and right). The DNA probes were incubated with varying amounts of protein in 20 μl of binding reaction mixture and electrophoresed on a 6% native polyacrylamide gel. Protein concentrations are indicated in [nM].

**Figure 4:** HMG I(Y) expression is increased in MCF-7 cells upon estrogen treatment or heregulin cDNA transfection. Southwestern blot analysis using radiolabeled wild-type (25), as the probe was performed with (A) and (B). Western blot analysis of HMG I(Y) was performed with (C). (A) Twenty five μg of proteins extracted from MCF-7 and MDA-MB 231 cells with various treatments for 48 hours were used for Southwestern analysis. C, control; E2, estradiol (10⁻⁷M); ICI, antiestrogen ICI 164,384 (10⁻⁷M); Tam, Tamoxifen (10⁻⁷M). (B) Twenty five μg of proteins extracted from MCF-7 and MDA-MB-231 cells were used for Southwestern analysis. MCF-7 cells transfected with the pRC/CMV vector only are indicated as V in left upper panel and as MCF-7/HRG-V in the right upper panel. Three MCF-7 clones transfected with heregulin-β2 cDNA are indicated as T₁, T₆, and T₇. The same amount of protein used in the Southwestern blot was subjected to Western blot analysis using anti-β-actin antibody. (C) Fifty μg proteins extracted from MCF-7 cells, MCF-7 cells treated with E₂, and MCF-7/T cells were used in the Western blot analysis using anti-HMG I(Y) antibody.

**Figure 5:** HMG I(Y) expression is reduced in MDA-MB-231 cells upon antisense-HRG transfection and MMP-9 inhibitor treatment. (A) Twenty μg of proteins extracted from MDA-MB-231/AS serious cells were used for Western blot analysis of HMG I(Y) and β-actin. MDA-MB-231 cells transfected with the pRC/CMV vector only are indicated as V. Three MDA-MB-231/AS clones transfected with antisense-HRG are indicated as C6, C23, and C31. (B) Boyden chamber assay: MDA-MB-231 cells were tested in the Boyden chamber assay in the presence or absence of
increasing concentrations (0-20 μM) of the MMP-9 inhibitor for 6 hours. Chemo-invasion was measured according to the number of cells transversing matrigel-coated filters. Data points present the mean from quadruplicate from a representative experiment. Standard deviation was calculated for each data point. (C) Twenty μg of proteins extracted from MDA-MB-231 cells with MMP-9 inhibitor treatments for 6 days at indicated concentration (0, 2.5, 5, and 10 μM) were used for Southwestern analysis using a radiolabeled wild-type (25) probe, and Western blot analysis of HMG I(Y) and β-actin. Quantitation of Southwestern blot and Western blot were done individually by phosphorimager and densitometer.
References


18. Yanagisawa, J., Ando, J., Nakayama, J., Kohwi, Y., and Kohwi-Shigematsu, T. A matrix attachment region (MAR)-binding activity due to a p114 kilodalton protein is found only in


Yansura, D., Abadi, N., Reeb, H., and Lewis, G. D. Identification of HRGs, a specific
and Yarden, Y. Isolation of the Neu/HER-2 stimulatory ligand: a 44 kDa glycoprotein that induces
53. Tang, C., Perez, C., Grunt, T., Waibel, C., Cho, C., and Lupu, R. Involvement of
heregulin-β2 in the acquisition of the hormone-independent phenotype of breast cancer cells.
preparation
human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading
I. SV-40 transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is
identical to that secreted by normal human macrophages. J. Biol. Chem., 264: 17213-17221,
1989.
57. Hua, J., and Muschel, R. J. Inhibition of matrix metalloproteinase 9 expression by a
ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res., 56: 5279-5284,
58. Thompson, E. W., Katz, D., Shima, T. B., Wakeling, A. E., Lippman, M. E., and Dickson,
R. B. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and


77. Stauss, F., and Varshavsky, A. A protein binds to a satellite DNA repeat at three specific sites that would be brought into mutual proximity by DNA folding in the nucleosome. Cell, 37: 889-901, 1984.


**Figure 1**

[Diagram showing gel electrophoresis with lanes labeled 1 to 7, and molecular weight markers (kDa) for 82, 47, and 20.]

**Figure 2**

**A**

[Diagram showing protein bands labeled M, Crude, and Purified with molecular weight markers (kDa) for 200, 166.3, 94.4, 66.2, 45, 31, 21.5, 14.4, and 6.5.]

**B**

[Diagram showing protein bands labeled Crude and Purified (1/100).]

**C**

[Diagram showing protein bands labeled p20 and HMG I, HMG I, and HMG Y.]

**Table**

<table>
<thead>
<tr>
<th>Cell line</th>
<th>HRG</th>
<th>ER</th>
<th>Vimentin</th>
<th>Invasive In vitro</th>
<th>Metastatic In vivo</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA-MB-453</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NT</td>
</tr>
<tr>
<td>SK-BR-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NT</td>
</tr>
<tr>
<td>BT-474</td>
<td></td>
<td>+++</td>
<td></td>
<td></td>
<td>-1</td>
</tr>
<tr>
<td>MCF-7</td>
<td></td>
<td>+++</td>
<td></td>
<td></td>
<td>-1</td>
</tr>
<tr>
<td>Hs578T</td>
<td>+++</td>
<td></td>
<td>++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>BT-549</td>
<td></td>
<td></td>
<td>++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>+++</td>
<td></td>
<td>++</td>
<td>+++</td>
<td>+</td>
</tr>
</tbody>
</table>
Figure 4

Figure 5